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Introduction:  Myxoid  liposarcomas  (MLS)  are  the  second  most  common  type  of  liposarcoma.  Although
some  MRI  ﬁndings  are  distinctively  characteristics  of MLS,  the  diagnosis  can  be  tricky  in tumors  with
a  large  portion  of  round  cells  (RC).  Known  predictors  of  an  unfavorable  outcome  include  age,  tumor
size,  high  RC  content  and  positive  resection  margins.  The  goal of this  retrospective  study  was  to  deﬁne
prognostic  factors  for  recurrence,  with  special  emphasis  on  the  percentage  of RCs  and  medical  care
provided  in  a  non-specialized  center.
Patients  and methods:  Twenty  patients  (11  women,  9  men)  with  a mean  age  of  44.3  years  (18–73) were
reviewed  after  a mean  of 55.9  months.  Six of  these  patients  had  been  operated  at a non-specialized  center.
The diagnostic  MRI  was  read  by a specialized  radiologist  and  the  resection  procedures  performed  by two
specialized  surgeons.  Tumors  were  labeled  as  either  “pure  myxoid  liposarcoma”  or “myxoid/round-cell
liposarcoma”.  The  local  recurrence-free  survival  rate  and  mortality  rate  were  calculated.
Results:  Fifteen  patients  had  undergone  an  MRI  during  the  initial  assessment.  The  typical  MRI  ﬁndings
of  MLS  were  present  in  four of  them.  The  MRI  suggested  a  non-speciﬁc  lesion  in  the  other  11  patients.
After  correlation  with  pathology  ﬁndings,  these  tumors  contained  more  than  5%  round  cells.  The  fourteen
patients  treated  at our facility  had undergone  a biopsy,  while  none  of the ones  treated  outside  did.  Five
patients  had  R0 resection  margins  and  15  had  R1 margins.  Prognostic  factors  for  recurrence  consisted
of  age, tumor  size  > 10 cm,  R1 resection  margins,  FNCLCC  grade  2 + R1  margins,  medical  care  at  a  non-
specialized  center,  and  > 5% round  cells.  There  were  eight  local  recurrences  and  three  metastases  (15%).
Two  patients  died  (90%  overall  survival  rate).
Discussion:  The  risk  of local  recurrence  was  3.86  times  greater  in  this  study  when  the  tumor  contained
more  than  5%  RCs,  which  is  consistent  with  published  data.  The  MLS diagnosis  was  made  only  four times
based  on  the  initial  MRI  because  misleading  nature  of high  RC tumors.  R1 resection  margins  are  a  risk
factor  for  local recurrence.  However,  cases  with  R1  margins  have  a recurrence  rate  that  is similar  to R0
cases  when  the  surgery  is performed  at  a  specialized  cancer  center.  Treatment  of MLS  in  a  non-specialized
center  is  a key  negative  prognostic  factor.  The  reported  rate  of  metastasis  varies.  Atypical  extrapulmonary
localizations  are  common,  and  often  multifocal.  MRI  has been  shown  to be  superior  at  detecting  secondary
lesions  and  some  have  suggested  that  a full-body  MRI  should  be  performed.
Conclusion:  Prognostic  factors  for the recurrence  of  myxoid  liposarcomas  have  been  identiﬁed.  MRI
analysis  is not  deﬁnitive  and must  be  supplemented  by  a biopsy.. IntroductionLiposarcomas are soft-tissue tumors in a broader class of mes-
nchymal tissue neoplasms, which have an adipocyte-derived cell
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population. These tumors make up 17–25% of all sarcomas, which
have an incidence of 30 cases per million [1,2].
The World Health Organization classiﬁcation includes ﬁve
sub-types, including myxoid liposarcomas (MLS) and round-cell
liposarcomas (RCLS) [3] (Fig. 1). MLS  is the second most com-
mon  type of liposarcoma. The disease spectrum is consistent with
that of other tumor types, ranging from well-differentiated pure
liposarcoma to dedifferentiated liposarcoma with high round-cell
content [4]. Well-known negative prognostic factor are patient age
104 M. Lemeur et al. / Orthopaedics & Traumatology
Fig. 1. Section through a myxoid liposarcoma after surgical resection showing typ-
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myxoid liposarcomas. In the other patients, the MRI  report listed
the presence of a non-speciﬁc heterogeneous mass with malig-
nant appearance. After correlation with pathology results, these
tumors contained more than 5% round cells. The ﬁve patients who
Table 1
Summary of study results.
Variable Value Percentage (%)
Age
Average 44.3
Range 18–73
Gender
Male 9 45
Female 11 55
Presentation
Primary 14 70
Post-resection R2 4 20
Post-recurrence 2 10
Tumor size
Average 11.675
Range 2–26
Biopsy 14 70
CT  scan 8 57.1
Surgery 5 35.7
Biopsy/excision 1 7
FNCLCC grade
Grade 1 11 55
Grade 2 9 45
Grade 3 0 0
“R” Classiﬁcation
R0 5 25
R1  15 75
Round cells
0–5% 5 45
10% 3 27.3
25% 2 18.2
>  25% 1 9.5cal  features such as myxoid and gelatinous tissue inﬁltrated by fat (superior pole
nd  center, arrows).
> 45 years), tumor size (> 10 cm), sub-aponeurotic location, high
istological grade, large percentage of round cells and positive
esection margins [5–7].
Magnetic resonance imaging (MRI) is essential for the diagnosis
f liposarcoma [4,8–10]. Although there are disease-speciﬁc MRI
riteria, the diagnosis can be tricky in tumors containing a large
umber of round cells [4,10]. Treatment of these lesions requires
 multidisciplinary team in a specialized cancer center [11–13].
LS  have the ability to metastasize to other soft tissues, including
erous ones, which can make patient monitoring more challenging
5,14,15].
The goal of the current study was to deﬁne prognostic factors
or local recurrence and metastasis, with special emphasis on the
ercentage of round cells and treatment at a non-specialized center.
. Patients and methods
A series of 20 patients who were treated surgically for MLS
etween January 2004 and February 2012 were reviewed ret-
ospectively. Patients were included if they had been referred
ithin our hospital network for consultation and treatment of
LS. Patients who were diagnosed and underwent tumor resection
t our facility were included, as where those who  underwent an
nplanned tumor resection at another facility.
All patients were treated and monitored. Patients who experi-
nced a recurrence during the follow-up period were compared to
hose who did not. The initial MRI  analysis was performed by a
ingle specialized radiologist. All of the surgical procedures were
erformed by two surgeons who were specialized in the care of
dult sarcomas.
The deﬁnitive diagnosis was made by a pathologist who spe-
ializes in sarcomas. The liposarcomas were labeled as either “pure
yxoid liposarcoma (MLS)” or “myxoid/round-cell liposarcoma
MRCLS)”. Histological grading was performed based on the FNCLCC
ystem (French Federation of Comprehensive Cancer Centers). The
uality of the surgical resection was deﬁned according to the “R”
lassiﬁcation of the Union for International Cancer Control. The
eed for additional treatment was determined in multidisciplinary: Surgery & Research 101 (2015) 103–107
meetings: radiation therapy for R1 tumors or FNCLCC grade 2 or 3
tumors; chemotherapy for metastatic lesions.
The data were analyzed statistically using the XLSTAT® software
(Addinsoft SARL, Paris, France). The local recurrence-free survival
time was  deﬁned as the period between the initial diagnosis and the
date of the last visit. The mortality rate was calculated. Differences
between the “local recurrence” and “recurrence-free” groups were
analyzed with a Chi2 test for the qualitative variables and Student’s
t-test for quantitative variables. A multivariate analysis was carried
using a Cox proportional hazards model. Statistical tests where the
P-value was below 0.05 were considered as being statistically sig-
niﬁcant. Survival rates were analyzed using Kaplan-Meier curves
to determine the risk of local recurrence, metastasis and death.
3. Results
The series consists of 20 patients (11 women, 9 men) who  were
operated for curative purposes between January 2004 and February
2012 (Table 1). The average age was 44.3 years (range 18 to 73).
The average follow-up was  55.9 months. The tumor was  located
in the lower limb in all patients: popliteal fossa in ﬁve patients
(25%), anterior aspect of thigh and sartorius muscle in four patients
(20%), adductor fossa in seven patients (35%) and gluteal area in two
patients (10%). The tumor was located in the anterior compartment
of the tibia in one patient and was  located in the infrapatellar fat
pad in one other patient.
Fifteen patients had undergone an MRI  during the initial assess-
ment. The disease-speciﬁc MRI  ﬁnding of a homogeneous mass
with combined T1 hyposignal and T2 hypersignal and intralesional
adipose tissue was  present in four patients, all of whom had pureLocal recurrence 8 40
Metastasis 3 15
Death 2 10
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sig. 2. Speciﬁc MRI ﬁndings of a pure myxoid tumor, namely T1 hyposignal (isosi
issue.
ad sought treatment at non-specialized centers did not initially
ndergo an MRI  evaluation.
Fourteen patients underwent a biopsy at our facility (8 under CT
ontrol), while none of the ones treated outside had a biopsy. An
nalysis of the biopsied tissue led to the ﬁnal diagnosis of MLS.
Surgical treatment was performed on 14 patients at our facility.
he resection was recorded as marginal in 3 patients (21.4%), wide
n 6 patients (42.8%) and radical in 5 patients (35.7%). The excision
as labeled as “intralesional” when the tumor was  opened during
he surgery, thereby contaminating the surgical site, which leads to
 high local recurrence rate. The excision was labeled as “marginal”
hen the tumor was removed macroscopically without opening it
ut the dissection plane was located near the tumor’s pseudocap-
ule; this leads to a risk of microscopic amounts of residual tumor
issue, which is also a cause of recurrence. This type of excision is
ften performed when the presence of nerve and vascular elements
revents a more extensive excision from being performed. The exci-
ion was labeled as “wide” when the entire tumor was removed
ith its pseudocapsule and a sleeve of healthy tissue around it from
he same compartment. This however does not prevent the pos-
ibility of “skip” metastasis in cases of highly malignant tumors.
he excision was labeled as “radical” or compartmental when the
ntire compartment containing the tumor and its pseudocapsule
ere removed, including fascia, muscle insertions and septa. The
isk of recurrence is very low (< 2%) in such cases [16].
The tumor resection surgery had been performed at a non-
pecialized center in the six other patients. Four were referred to
s for consultation after a type R2 resection and two after local
ecurrence.
The pathology evaluation identiﬁed tumors that were 2 to 26 cm
n size. Nine were pure myxoid liposarcomas and 11 were classi-
ed as myxoid/round-cell liposarcomas, 6 of which had >5% round
ells. There were 11 grade 1 tumors and 9 grade 2 tumors (FNCLCC
cale). The resection margins were graded as R0 in 5 cases and R1 in
5 cases, 10 of which were from “planned” surgical procedures. The
iagnosis was conﬁrmed by the detection of t(12;16) chromosome
ranslocation, speciﬁcally TLS-CHOP fusion [5]. Adjuvant radiation
herapy was carried out in the 15 patients with R1 resection mar-
ins or grade 2 tumors. The lesions were subfascial in all of these
ases; a small tumor size did not exclude the patient from adjuvant
adiation therapy. Adjuvant chemotherapy was prescribed in the
hree patients with metastasis.
There were eight cases of local recurrence. Negative progno-
tic factors consisted of higher age (mean of 52.25 in those witho muscle) and T2 hypersignal in a homogeneous mass with intralesional adipose
recurrence), tumor size (> 10 cm)  in combination with age, R1
resection margins, FNCLCC grade 2 tumor with R1 margins, treat-
ment carried out in non-specialized center and > 5% round-cell
content. Only the latter component was  a statistically signiﬁcant
predictor of recurrence (P = 0.047).
Three patients had a metastasis; all had tumors with a large
portion of round cells. Secondary lesions were found in extrapul-
monary locations such as bone, muscle and the retroperitoneal
space. The estimated metastasis risk was  15%. Two  of these patients
died. The survival rate for the patient cohort was  90% with a maxi-
mum  follow-up of 8 years.
4. Discussion
This was  a retrospective study of a rare disease with short inclu-
sion and follow-up periods; all of these factors combine to reduce
the statistical power of this study. There are only seven published
studies on myxoid/round-cell liposarcoma [5,6,17–21]. The small
number of patients also limits the interpretation of any statistical
tests for prognostic factors.
The percentage of round cells was the strongest prognostic
factor, as it negatively impacted local recurrence, metastasis and
survival. Grading of the round-cell content of tumors is based on
three levels and a 5% threshold. The lowest grade corresponds to
pure MLS; intermediate-grade tumors contain 0 to 5% RCs and the
highest-grade tumors contain more than 5% RCs. In this study, 11
of the 20 patients (55%) had RCs in their tumor; 6 of them had
more than 5%. Among these 6 patients, 5 had a local recurrence.
This resulted in an 83% rate of recurrence for tumors with > 5% RCs
and 21.5% rate for tumors with < 5% RCs.
In this study, the risk of local recurrence was  3.86 times greater
if the tumor contained more than 5% RCs; this is consistent with the
3.4 fold increase in risk found in a recent study [17]. There is also
evidence that the “low-grade” nature of pure myxoid liposarcomas
results in a 77% recurrence-free survival rate at 10 years [22].
Imaging ﬁndings are not deﬁnitive; many pitfalls have been
described [4,8–10]. Disease-speciﬁc MRI  ﬁndings only occur with
pure myxoid liposarcoma or tumors with a low percentage of RCs
(Fig. 2). Tumors with a high percentage of RCs have an atypical
appearance (Fig. 3). In the current study, the MLS  diagnosis was
strongly suggestive in only 4 of 20 patients based on the initial
MRI.
R1 resection margins are an important risk factor for local recur-
rence [5,6,17–21,23]. However, a local recurrence rate similar to R0
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Fig. 3. Tumors containing a large percentage of round cells are more heterogeneous,
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of  an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg
Br  2008;90(2):203–8.aking them trickier to diagnose using MRI.
urgery can be obtained when the excision procedure is planned by
 specialized surgeon who has decided before the surgery to accept
arrow margins in high-risk areas or areas in close proximity to
ascular, nerve or bone structures [12,23–25]. The local recurrence
ate was 23% in the current study when the surgery was planned
ccordingly, which is comparable to published rates [5,6,17–21].
Treatment of MLS  at a facility that is not specialized in cancer
are is an important risk factor for local recurrence. Engström et al.
12] found a 47% recurrence rate for tumors operated in this setting.
handrasekhar et al. [11] found a 59% rate of residual tumors out
f 363 cases. In the current study, six patients were initially treated
n a non-specialized center. Four of them had a recurrence; four
ad an “intralesional” excision; only one had a preoperative MRI;
one of the patients had a preoperative biopsy; two experienced
 metastasis and one died. The French National Cancer Institute
INCa) has set up an accredited network of facilities in 2010 that
ncludes three specialized centers and 25 expert centers through-
ut France. Patients with a suspected sarcoma must be referred
o one of these centers so they can beneﬁt from care given by a
pecialized team.
The published rate of MLS  metastasis ranges from 14 to 32%
5,6,17–21]. Atypical extrapulmonary localizations are common,
nd often multifocal [5,14–16,21,26]. MRI  has been shown to be
uperior at detecting secondary lesions [27,28]. It has also been
uggested that patients undergo a whole-body MRI  [29]. This exam-
nation was shown to be feasible in a small series of patients and
as good sensitivity and speciﬁcity. Nevertheless, it cannot be per-
ormed in all patients and should be limited to those who have the
ighest risk of an unfavorable outcome based on the prognostic
actors.
MLS  are atypical when it comes to adjunct treatments. They
re more sensitive to radiation therapy [30–32] and chemotherapy
33,34] than other soft-tissue sarcomas. Trabectedin is a promis-
ng therapeutic candidate [35]. The relatively high recurrence rate
hen compared to other centers (28% vs. 10%) highlights the ben-
ﬁt of treatment in a specialized center and also points to a beneﬁt
f neoadjuvant radiation therapy [18,19,36]. This could be partic-
larly relevant for large tumors with a high risk of recurrence, as
t may  be possible to reduce the tumor’s volume before it is surgi-
ally resected. Radiation therapy was used as an adjuvant in certain
atients in the current study. The studies reporting a better sur-
ival rate were performed on patients who received neoadjuvant
[: Surgery & Research 101 (2015) 103–107
chemotherapy [6,17]. Nevertheless, the treatment protocols are not
well deﬁned and have not been standardized.
5. Conclusion
The goal of this study was to deﬁne prognostic factors for myx-
oid liposarcomas. The risk factors for local recurrence found in this
study were consistent with the ones outlined in previously pub-
lished studies: patient above 45 years of age, tumor size greater
than 10 cm,  positive resection margins with or without FNCLCC
grade 2, more than 5% round-cell content and treatment carried
out at a facility that is not specialized in sarcoma care.
Non-planned surgery was a predictor of unfavorable outcomes.
Based on these ﬁndings, sarcoma patients should only be treated in
specialized centers, especially since MRI  and biopsy examinations
can be tricky and misleading. Sarcoma patients who  are referred
after being treated in non-specialized centers have a greater risk of
local recurrence.
MLS  are atypical tumors that are very sensitive to radiation
therapy and chemotherapy, and have an unusual ability to metas-
tasize in locations other than the lungs. The threshold between
intermediate-grade and high-grade corresponds to a 5% round-cell
content. High-grade tumors (> 5% round cells) have a higher risk of
metastasis. The potential beneﬁt of neoadjuvant radiation therapy
and adjuvant chemotherapy must be evaluated in these patients.
This subset of patients is also a candidate group for research into
new treatments.
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